8:30 am
Morning Coffee

8:50 am Chair’s Opening Remarks

  • Shaker Mousa Professor ACPHS and Co-Founder, Nano-Pharmaceuticals

Translational Effects & Detailed Analysis of Integrins

9:00 am : Evaluating the Safety and Tolerability of PLN-74809, a Dual-Selective Inhibitor of Integrins αvβ6 and αvβ1

Synopsis

  • No treatment-related effects in chronic GLP toxicology studies; NOAEL set at the highest dose tested
  • PLN-74809 has been administered to over 450 study participants to date and shown to be well tolerated
  • Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-IPF Phase 2a trial continue without modification and proceed to evaluate dosing at 320mg

9:30 am Analyzing Radiopharmaceutical Imaging & Therapy Targeting AvB6 Integrin

Synopsis

  • Looking at the unmet need in pancreatic cancer
  • Exploring the value of imaging in integrin analysis
  • Delving into the therapeutic values of radiopharmaceutical imaging

10:00 am
Morning Networking Break

The Therapeutic Approaches of Integrins & Their Implications in Disease

10:30 am Integrin α10β1 Selected MSCs – A Superior Therapeutic Approach

Synopsis

  • Xintela’s integrin biomarker technology platform has potential to reach $10bn commercials through OA, GBM and TNBC

11:00 am Targeting integrin α10β1 in Aggressive Cancer

Synopsis

  • Targinta has selected its first lead drug candidate, TARG10, a therapeutic antibody targeting integrin α10β1
  • TARG10 has shown strong activity on cancer cells and in preclinical tumor models, with significant inhibitory effects on both growth and metastasis in triplenegative breast cancer models

11:30 am MORF-057 – A selective oral α4B7 Integrin Inhibitor for Inflammatory Bowel Disease

Synopsis

  • α4B7 Integrin inhibition is a clinically validated mechanism of action to treat IBD
  • Utilizing the MInT platform, we have identified the highly selective oral Inhibitor MORF-057 and advanced it into clinical studies
  • Phase 1 clinical data support the initiation of Phase 2 clinical trials in UC

12:00 pm
Networking Lunch

The Clinical Safety of Integrins & New Developments

1:00 pm Delving into the Integrin α4β7 Small Molecule Inhibitor

Synopsis

  • Taking a look at the therapeutic properties of integrins and how they can be used in clinic to deliver treatment to patients

1:30 pm An Analysis of Integrins for Nano-Targeted Delivery

  • Shaker Mousa Professor ACPHS and Co-Founder, Nano-Pharmaceuticals

Synopsis

• Looking at the evidence which has demonstrated that nanobiotechnology and
nanomedicine have tremendous potential to affect numerous aspects of cancer
and other disorders, in both early diagnosis and targeted therapy
• The utilization of nanotechnology for the development of new Nano-carrier
systems has the potential to offer improved targeted delivery through increased
solubility and sustained retention and more importantly active targeting.

2:00 pm
Chair’s Closing Remarks & End of Day Two

  • Shaker Mousa Professor ACPHS and Co-Founder, Nano-Pharmaceuticals